Laboratory diagnostics of lipid metabolism disorders: modern innovations in new Russian and international recommendations

Arabidze G.G.; Puhaeva A.A.; Pravdivtseva E.V.

doi:https://doi.org/10.17116/labs20241301120

Close metadata

Recommended articles:

The role of quantitative body composition analysis in population in the assessment and monitoring of cardiovascular risk metabolic factors. Russian Journal of Preventive Medicine. 2024;(12):128-134

Exploring the capability of the cardiovascular risk evaluation using the vital functions integral analysis. Russian Journal of Preventive Medicine. 2025;(3):53-59

Coronavirus infection as a risk factor in occlusive-stenotic lesions of the brachiocephalic arteries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52

Prevalence and role of elevated serum lipoprotein(a) in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48

On the path to personalized cardiology: prospects of precise assessment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215

Two years experience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220

The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts. Russian Journal of Preventive Medicine. 2025;(4):7-15

Creating an index reflexing cardiovascular risk using the vital functions integral analysis. Russian Journal of Preventive Medicine. 2025;(4):82-88

QRISK-3 cardiovascular risk assessment algorithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69

Socio-economic damage caused by elevated low-density lipoprotein cholesterol levels. Medical Technologies. Assessment and Choice. 2025;(2):88-98

Abstract:

New data on the laboratory diagnostics of lipid metabolism disorders are presented based on the latest guidelines of the Russian Society of Cardiology (from 2023) and a joint document published in 2020 by the Joint Consensus Panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) “Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM” with the aim of improving the laboratory diagnostics of atherogenic dyslipidemias, introducing a modern arsenal of laboratory tests into widespread clinical practice and improving knowledge about modern methods for diagnosing lipid metabolism disorders.

Keywords:

cardiovascular disease caused by atherosclerosis

dyslipidemia

cardiovascular risk

laboratory diagnosis of lipid metabolism disorders

Authors:

Arabidze G.G.

Russian Medical Academy for Continuing Professional Education

ORCID: 0000-0003-3370-3506

Puhaeva A.A.

Russian Medical Academy for Continuing Professional Education

ORCID: 0000-0002-1445-1561

Pravdivtseva E.V.

Russian Medical Academy for Continuous Professional Education

ORCID: 0009-0002-2626-3872

Received:

30.04.2023

Accepted:

22.06.2023

Close metadata

References:

Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650-1656.
Newman WP, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL, Williamson GD, Webber LS, Berenson GS. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314:138-144.
Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, Ibanez B, Lopez-Melgar B, Laclaustra M, Oliva B, Mocoroa A, Mendiguren J, Martinez de Vega V, Garcia L, Molina J, Sanchez-Gonzalez J, Guzman G, Alonso-Farto JC, Guallar E, Civeira F, Sillesen H, Pocock S, Ordovas JM, Sanz G, Jimenez-Borreguero LJ, Fuster V. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: The PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation. 2015;131:2104-2113. https://doi.org/10.1161/CIRCULATIONAHA.114.014310
Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020 Mar 26;58(4):496-517. PMID: 31855562. https://doi.org/10.1515/cclm-2019-1253
Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Clinical recommendations “Lipid metabolism disorders”. Russian Society of Cardiology. M. 2023. (In Russ.). https://scardio.ru/news/novosti_obschestva/novye_klinicheskie_rekomendacii_po_narusheniyam_lipidnogo_obmena
Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-1379. https://doi.org/https://doi.org/10.1194/jlr.R200004-JLR200
Chapman MJ, Laplaud PM, Luc G, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.
Hegele RA, Borén J, Ginsberg HN, Arca M, Averna M, Binder CJ, Calabresi L, Chapman MJ, Cuchel M, von Eckardstein A, Frikke-Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Lütjohann D, Parhofer KG, Raal FJ, Ray KK, Remaley AT, Stock JK, Stroes ES, Tokgözoğlu L, Catapano AL. Rare dyslipidaemias, from phenotype to genotype to management: A European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 Jan;8(1):50-67. Epub 2019 Sept 30. PMID: 31582260. https://doi.org/10.1016/S2213-8587(19)30264-5
Tribble DL, van den Berg JJ, Motchnik PA, Ames BN, Lewis DM, Chait A, Krauss RM. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA. 1994;91:1183-1187. https://doi.org/10.1073/pnas.91.3.1183
Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry. 1998;37:12867-12874. https://doi.org/10.1021/bi980828m
Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr Opin Lipidol. 2014;25:221-226. https://doi.org/10.1097/MOL.0000000000000067
Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305-311. https://doi.org/10.1097/MOL.0b013e32833b7756
Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23:97-104.
Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis. 1990;83:59-67. https://doi.org/10.1016/0021-9150(90)90131-2
Li KM, Wilcken DE, Dudman NP. Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem. 1994;40:571-573.
Mora S. Advanced lipoprotein testing and subfractionationare not (yet) ready for routine clinical use. Circulation. 2009;119:2396-404. https://doi.org/10.1161/CIRCULATIONAHA.108.819359
Joint Consensus Initiative Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496-517. https://doi.org/10.1515/cclm-2019-1253
Descamps OS, Bruniaux M, Guilmot PF, Tonglet R, Heller FR. Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis. 2004;172:287-298. https://doi.org/10.1016/j.atherosclerosis.2003.11.002
O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146. https://doi.org/10.1016/j.jacc.2004.03.046
Kit BK, Carroll MD, Lacher DA, Sorlie PD, DeJesus JM, Ogden C. Trends in serum lipids among US youths aged 6 to 19 years, 1988—2010. JAMA. 2012;308:591-600. https://doi.org/10.1001/jama.2012.9136
Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA. 2012;308:1545-1254. https://doi.org/10.1001/jama.2012.13260
Berry JD, Dyer A, Cai X, et al. Lifetime risk of cardiovascular disease. N Engl J Med. 2012;366:321-329. https://doi.org/10.1056/NEJMoa1012848
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani. SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA. Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. https://doi.org/10.1016/j.jacc.2018.11.003
Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 05;295(13):1556-1565. Epub 2006 Mar 13. PMID: 16533939. https://doi.org/10.1001/jama.295.13.jpc60002
Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078-2087. https://doi.org/10.1056/NEJMoa1110874
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47. https://doi.org/10.1126/science.3513311
Glueck CJ, Kunkel R, Tieger M. Pathophysiologic relationships and linkage among triglycerides, hypocholesterolemia, and depression. In: Hillbrand M, Spitz RT, eds. Lipids, health, and behavior. American Psychological Association. 1997:99-112. https://doi.org/10.1037/10259-005.
Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161-172. https://doi.org/10.1016/j.cell.2015.01.036
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953-1975. https://doi.org/10.1194/jlr.R071233
Van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES. Oxidized phospholipids on lipoprotein (a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611-624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838
Boffa MB, Koschinsky ML. Screening for and management of elevated Lp(a). Curr Cardiol Rep. 2013;15(11):417. https://doi.org/10.1007/s11886-013-0417-8
Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60. https://doi.org/10.1172/JCI115855
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000;102:1082-1085. https://doi.org/10.1161/01.CIR.102.10.1082
Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635-642. https://doi.org/10.1161/CIRCULATIONAHA.113.004406
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146-1156. https://doi.org/10.1016/j.jacc.2012.12.023
O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63:520-527.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844-2853. Epub 2010 Oct 21. PMID: 20965889; PMCID: PMC3295201. https://doi.org/10.1093/eurheartj/ehq386
Melita H, Manolis AA, Manolis TA, Antonis S, Manolis AS. Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. J Cardiovasc Pharmacol. 2021 Oct. 20. Online ahead of print. https://doi.org/10.1097/FJC.0000000000001160
Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-423. https://doi.org/10.1001/jama.2009.1063
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjaerg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J. European Prospective Investigation Into Cancer and Nutrition_Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A Mendelian randomization analysis. JAMA Cardiol. 2018;3:619-627. https://doi.org/10.1001/jamacardio.2018.1470
Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study. Circ Genom Precis Med. 2018;11:e001696. https://doi.org/10.1161/CIRCGEN.117.001696
Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? Prog Lipid Res. 2017;68:57-82. https://doi.org/10.1016/j.plipres.2017.09.001
Di Bartolo BA, Psaltis PJ, Bursill CA, Nicholls SJ. Translating evidence of HDL and plaque regression. Arterioscler Thromb Vasc Biol. 2018;38:1961-1968. https://doi.org/10.1161/ATVBAHA.118.307026
Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019;51(2):131-141. https://doi.org/10.1016/j.pathol.2018.09.062
Myers GL, Cooper GR, Henderson LO, Hassemer DJ, Kimberly MM. Standardization of lipid and lipoprotein measurement. Rifai N Warnick GR Domoniczak MH eds. AACC Press Washington. Handbook of lipoprotein testing. 2000;717-748.
Ferrinho C, Alves AC, Bourbon M, Duarte S. Applicability of Martin-Hopkins formula and comparison with Friedewald formula for estimated low-density lipoprotein cholesterol in e_COR study population. Rev Port Cardiol (Engl Ed). 2021 Oct;40(10):715-724. Epub 2021 Aug 11. PMID: 34857108. https://doi.org/10.1016/j.repce.2021.07.001
Johns Hopkins Medicine. Johns Hopkins medical apps. LDL Cholesterol Calculator. Accessed August 26, 2019. https://www.hopkinsmedicine.org/apps/all-apps/ldl-cholesterol-calculator
Grundy SM, Becker D, Clark LT, et al. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. September 2002. NIH Publication No. 02-5215.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sept 7;42(34):3227-3337. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468. PMID: 34458905. https://doi.org/10.1093/eurheartj/ehab484
Marc S Sabatine, Stephen D Wiviott, KyungAh Im., Sabina A Murphy, Robert P Giugliano. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018;3(9):823-828. https://doi.org/10.1001/jamacardio.2018.2258
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. https://doi.org/10.1056/NEJMoa1912387
Arabidze GG, Zhloba AA, Roytman AP. Laboratory diagnosis of lipid metabolism disorders and the development of atherosclerosis. Atherosclerosis and Dislipidemia. 2022;4(45):5-16. (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2021.04.0001
Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Bubnova MG, Balakhonova TV, Gurevich VS, Kachkovsky MA, Konovalov GA, Konstantinov VO, Malyshev PP, Pokrovsky SN, Sokolov AA, Sumarokov AB, Gornyakova NB, Obrezan AG, Shaposhnik II, Antsiferov MB, Ansheles AA, Aronov DM, Akhmedzhanov NM, Barbarash OL, Boytsov SA, Bubnova MG, Voevoda MI, Galstyan GR, Galyavich AS, Drapkina OM, Duplyakov DV, Eregin SYa, Karpov RS, Karpov YuA, Koziolova NA, Kosmacheva ED, Nebireidze DV, Oleinikov VE, Ragino YuI, Skibitsky VV, Smolenskaya OG, Filippov AE, Khalimov YuSh, Chazova IE, Shestakova MV, Yakushin SS. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII revision. Atherosclerosis and Dislipidemia. 2020;1(38):7-40. (In Russ.).
Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Balakhonova TV, Gurevich VS, Zelveyan PA, Murataliev TM, Myrzakhmetova GS, Sudzhaeva OA, Shek AB, Azizov VA, Gornyakova NB, Kachkovsky MA, Malyshev PP, Pokrovsky SN, Sokolov AA, Sumarokov AB, Obrezan AG, Shaposhnik II, Antsiferov MB, Ansheles AA, Aronov DM, Akhmedzhanov NM, Barbarash OL, Boytsov SA, Bubnova MG, Voevoda MI, Galstyan GR, Galyavich AS, Drapkina OM, Duplyakov DV, Eregin SYa, Karpov RS, Karpov YuA, Koziolova NA, Konovalov GA, Konstantinov VO, Kosmacheva ED, Nedogoda SV, Oleinikov VE, Ragino YuI, Skibitsky VV, Smolenskaya OG, Khalimov YuSh, Chazova IE, Filippov AE, Shestakova MV, Yakushin SS. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, Russia) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian Heart Journal. 2020;2:6-29. (In Russ.). https://doi.org/10.38109/2225-1685-2020-2-6-29